Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study

The Lancet. Haematology
Bogdan DumitriuPhillip Scheinberg

Abstract

T-cell large granular lymphocytic leukaemia (T-LGL) is a lymphoproliferative disease that presents with immune-mediated cytopenias and is characterised by clonal expansion of cytotoxic CD3+ CD8+ lymphocytes. Use of methotrexate, ciclosporin, or cyclophosphamide as first therapy improves cytopenias in 50% of patients, but long-term use of these can lead to toxicity. We aimed to explore the activity and safety of alemtuzumab, an anti-CD52 monoclonal antibody, in patients with T-LGL. We did this single-arm, phase 2 trial in consecutively enrolled adults with T-LGL referred to the National Institutes of Health in Bethesda, MD, USA. Alemtuzumab was given intravenously at 10 mg per day for 10 days. The primary endpoint was haematological response at 3 months after infusion. A complete response was defined as normalisation of all affected lineages, and a partial response was defined in neutropenic patients as 100% increase in the absolute neutrophil count to more than 5 × 10(8) cells per L, and in those with anaemia, as any increase in haemoglobin of 20 g/L or higher observed in at least two serial measurements 1 week apart and sustained for 1 month or longer without exogenous growth factors support or transfusions. Analysis was by in...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Feb 13, 2001·The Journal of Clinical Investigation·P K Epling-BurnetteT P Loughran
Sep 21, 2001·British Journal of Haematology·F WillisE C Gordon-Smith
Apr 15, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·J Joseph MelenhorstA John Barrett
Aug 23, 2005·Leukemia Research·Wing-Yan AuYok-Lam Kwong
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan StilgenbauerUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Apr 7, 2010·Leukemia & Lymphoma·Anne F FortuneElisabeth Vandenberghe
Nov 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elaine M SloandNeal S Young
Dec 31, 2010·Blood·Thierry Lamy, Thomas P Loughran

❮ Previous
Next ❯

Citations

Jan 25, 2017·Blood·Thierry LamyThomas P Loughran
Jul 22, 2019·Brain : a Journal of Neurology·Steven A GreenbergDavid M Dorfman
Jun 22, 2017·Leukemia & Lymphoma·Srinivasa R SanikommuJaroslaw P Maciejewski
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Aline Moignet, Thierry Lamy
Mar 7, 2019·Nature Reviews. Rheumatology·Steven A Greenberg
Sep 15, 2017·British Journal of Haematology·Swapna ThotaJaroslaw P Maciejewski
Jun 11, 2020·British Journal of Haematology·Zachary BraunsteinJonathan E Brammer
Oct 6, 2019·Best Practice & Research. Clinical Haematology·Gregorio BarilàRenato Zambello
Mar 4, 2021·Blood·Carmelo Gurnari, Jaroslaw P Maciejewski
Apr 6, 2021·American Journal of Hematology·Ning DongLubomir Sokol
Aug 19, 2021·Best Practice & Research. Clinical Haematology·Bhavisha A PatelNeal S Young
Apr 30, 2020·Acta Haematologica·Christina PohJoseph Tuscano

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR
biopsy
density gradient centrifugation
electrophoresis
MDS
hormone replacement

Clinical Trials Mentioned

NCT00345345

Software Mentioned

GraphPad
Qiagen DataAnalysis WebPortal
STAT
GraphPad Prism
FlowJo

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.